Chest Infections |

Current Use of Ceftaroline for Community-Acquired Bacterial Pneumonia (CABP) in US Hospitals: Length of Stay and Total Cost From the CAPTURE Study FREE TO VIEW

Xingyue Huang, PhD; Alena Jandourek, MD; Phillip Cole, MD; David Friedland, MD
Author and Funding Information

Forest Research Institute, Inc., Jersey City, NJ

Chest. 2013;144(4_MeetingAbstracts):259A. doi:10.1378/chest.1704989
Text Size: A A A
Published online


SESSION TITLE: Respiratory Infections Posters

SESSION TYPE: Original Investigation Poster

PRESENTED ON: Wednesday, October 30, 2013 at 01:30 PM - 02:30 PM

PURPOSE: Ceftaroline (CPT) is a cephalosporin with broad spectrum activity against Gram-negative and Gram-positive pathogens including MRSA. CAPTURE is a multicenter, retrospective cohort study to characterize the use of Teflaro® for hospitalized patients with Acute Bacterial Skin and Skin Structure Infections (ABSSSI) or CABP. This analysis focuses on the economic outcomes of the CABP patients.

METHODS: Data collection was conducted at 30 participating US study centers. Medical charts were reviewed to extract patient level demographic, clinical and economic outcomes data. Descriptive analysis was conducted for patient demographics, clinical characteristics and clinical response. Hospital length of stay (LOS) and total charges were analyzed for all CABP patients and patient subgroups.

RESULTS: 272 CABP patients were included in this analysis with mean age of 63.1 years (≥65 years old 48.9%, males 53.3% and whites 57.4%). 75.8% patients had relevant medical history including structural lung disease (41.5%), prior pneumonia (24.3%), gastroesophageal reflux (22.8%) and CHF (18.8%). 29.4% patients were smokers (13.9% current smokers). CPT was used as monotherapy in 36.8% of the patients. 66 (24.3%) patients had ICU stay with median duration of stay of 7 days. Mean (median) CPT treatment duration was 6.3 (5) days for all patients and 6.3 (6) and 6.3 (5) days for monotherapy and adjunct therapy patient groups, respectively. The majority of patients achieved clinical success (76.8%) and discharged to either home (58.1%) or another care facility (37.5%). Mean (median) LOS and total hospital charge were 12.7 (9) days and $102,617 ($56,400) for all patients. Mean and median total hospital charges for CPT monotherapy were lower than adjunct therapy.

CONCLUSIONS: Real world results show that CPT is an effective treatment as 1st line therapy with average duration of 6 days. Mean total hospital charges for CPT monotherapy is lower than CPT adjunct group.

CLINICAL IMPLICATIONS: Real world results show that CPT is an effective treatment as 1st line therapy with average duration of 6 days.

DISCLOSURE: Xingyue Huang: Employee: Full time employee at Forest Research Institute, Inc. Alena Jandourek: Employee: Full time employee at Cerexa, Inc. Phillip Cole: Employee: Full time employee at Cerexa, Inc. David Friedland: Employee: Full time employee at Cerexa, Inc.

No Product/Research Disclosure Information




Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543